The p51/p63 gene, a novel member of the p53 gene family, has recently been identified at 3q27-9. There are at least six major isotypes of p51/p63 mRNA transcripts. p51A/TAp63␥ has the potential to induce apoptosis and growth suppression in a manner similar to p53, and other isotypes may suppress the p53 and p51A/TAp63␥ genes in a dominant-negative manner. We analyzed the mutation and expression of the p51/p63 gene in 80 cases of chronic myelogenous leukemia (CML) to evaluate its role in blastic transformation. Expression of the p51/p63 gene was detected in 74 cases. The ␣ isotype of p51/p63 transcripts was dominantly expressed in 72 of these 74 cases. There was no correlation between the isotypes of p51/p63 transcripts and the clinical phase. Mutations of the p51/p63 gene were found in six cases. All these mutated cases expressed p51B/TAp63 ␣. In four of the six cases, the mutations were within a limited region (codon 151-170) corresponding to the DNA-binding domain. We hypothesized that this limited region is a hot spot for mutation of the p51/p63 gene. Mutations of the p53 gene were found in four cases of CML in blastic crisis (BC). Frequencies of the p51/p63 and p53 gene mutations were higher in BC (p51/p63 gene, 11.8%; p53 gene, 7.8%) than in the chronic phase (p51/p63 gene, 1.5%; p53 gene, 0%). The p51/p63 gene mutation may act similarly to the p53 gene mutation as a genetic alteration potentially responsible for the progression of CML. Leukemia (2001) 15, 1729-1734.
Introduction
Tumor suppression by p53 is at least partially due to its ability to activate transcription of certain genes involved in cell cycle control and apoptosis (programmed cell death). Abnormalities of the p53 gene are common in human cancers and may be of prognostic significance in hematologic malignancies. [1] [2] [3] [4] The progression of chronic myelogenous leukemia (CML) from the chronic phase (CP) to blastic crisis (BC) is often associated with accumulation of multiple chromosomal and genetic aberrations. However, the precise molecular events accounting for blastic transformation of CML are still unknown. Many studies suggest that the p53 gene mutation, N-ras gene mutation and c-myc amplification are responsible for the clinical progression in only a minority of CML cases. [5] [6] [7] The p73 and p51/p63 genes, a novel p53 family genes, have recently been discovered. [8] [9] [10] The p73 gene is mapped to chromosome 1p36. 33 , and the p51/p63 gene is mapped to chromosome 3q27-9. The amino acid sequence in the central major region of the p51/p63 gene, which corresponds to the DNA-binding domain in the p53 gene family, shows 60% identity with the sequence of the p53 gene. The p51/p63 gene expresses at least six major transcripts, derived from alterna- tive splicing events. 10 Three of the p51/p63 variants are called TA type and encode proteins with transactivation, DNA binding and oligomerization domains. The other three, which lack the acidic N-terminal domain, are called delta (⌬) N type. Both types have different C-terminals described as ␣ (B), ␤ and ␥ (A). 9, 10 p51A, which has the N-terminal domain and the shortest C-terminal, means the same as TAp63␥ ( Figure  1 ). 9, 10 p51B, which has the N-terminal domain and the longest C-terminal means the same as TAp63 ␣ (Figure 1) . 9, 10 Like the p53 gene, p51A/TAp63 ␥ activates the transcription of p21
Waf1/Cip1 and BAX, 11 and induces apoptosis. 9 Thus, p51A/TAp63 ␥ is considered to be a tumor suppressor gene. Another variant, for example, the ⌬N type and p51B/TAp63 ␣, may possess oncogenic properties and act in a dominantnegative manner toward p53 and p51A/TAp63 ␥ transcripts. 10 Gene knockout studies have shown that the p51/p63 gene is essential for skin formation and for the generation of apical ectodermal ridges to induce development of the extremities. 12, 13 The p51A/TAp63 ␥ isotype can induce erythro-differentiation in Friend erythroleukemia cells. 9 We analyzed the expression and mutation of the p51/p63 gene under the hypotheses that the p51/p63 gene may work at hematological differentiation and that its aberration may be associated with the blastic transformation of CML.
Materials and methods

Patients
We studied 116 bone marrow samples obtained from 80 patients with CML in various clinical phases (65 in CP, seven in accelerated phase (AP), and 44 in BC). The diagnosis of CML was made on the basis of clinical features, hematological data, and Philadelphia chromosome. In 34 patients, both cytogenetic and molecular analyses were performed in more than one phase, ie in CP and BC (30 patients), in CP and AP (two patients), and in CP, AP, and BC (two patients). Fifty normal bone marrow (BM) or peripheral blood (PB) samples were obtained to study the expression and polymorphisms of the p51/p63 gene. These samples were obtained with the patients' informed consent.
Cytogenetic analysis
Cytogenetic analysis was performed after culturing the cells for 24-48 h. Twenty metaphase cells of BM or PB were analyzed after Trypsin-Giemsa banding. 14 
Extraction of RNA and DNA
Mononuclear cells (MNCs) were obtained by Ficoll-Hypaque centrifugation (Lymphoprep, Neegard, Norway). The total Leukemia RNA of BM-MNCs was extracted with a RNAzol kit (Biotex Laboratories, Houston, TX, USA), using a modification of the technique described previously.
14 Total cellular DNA was extracted from BM-MNCs by protease K digestion, phenolchloroform extraction, and ethanol precipitation. 15 Reverse-transcription polymerase chain reaction (RT-PCR) for expression analysis of the p51/p63 gene cDNA was prepared from 0.5 g of total RNA using a random hexamer primer according to the our original protocol. 14 cDNA conversion mixture was amplified by PCR. The following primers were used : TA, 5Ј-ATGTCCCAGAGCACACAG-3Ј and 5Ј-AGCTCATGGTTGGGGCAC-3Ј; ⌬N, 5Ј-CAGA CTCAATTTAGTGAG-3Ј and 5Ј-AGCTCATGGTTGGGGCAC-3Ј; ␣, 5Ј-GACTTATGAAATGCTGTTGAA-3Ј and 5Ј-TCGCA-CAGCATCAATAACACG-3Ј; ␥, 5Ј-GACTTATGAAATGCTG TTGAA-3Ј and 5Ј-CGTCAGATTGTTTTGGAGTTT-3Ј. PCR conditions were as follows: preheating at 94°C for 2 min, followed by 35 cycles of 94°C for 1 min, 52°C (TA and ⌬N) or 55°C (␣ and ␥) for 1 min, and 72°C for 1 min, with a final extension at 72°C for 5 min. 10, 16 The RT-PCR products were then separated on 2% agarose gels, stained with ethidium bromide, and photographed.
RT-PCR for mutation analysis of the p51/p63 transcripts
cDNAs of CML patients were subjected to PCR singlestranded conformation polymorphism (SSCP) analysis to search for mutations of the p51/p63 gene. To prepare primers for analysis we modified eight sets of primers designed by Sunahara et al, 17 covering the entire coding regions of both p51A/TAp63 ␥ and p51B/TAp63 ␣. Each fragment was amplified using the following primer pairs: p51A 1F 5Ј-AAA-GAAAGTTATTACCGATC-3Ј and p51A1R 5Ј-CGCGTG GTCTGTGTTATAGG-3Ј; p51A2F 5Ј-CATGGACCAGCA-GATTCAGA-3Ј and p51A2R 5Ј-CATCACCTTGATCTGGATG-3Ј; p51A3F 5Ј-CCACCTGGACGTATTCCACT-3Ј and p51A3R 5Ј-TGGCTCATAAGGTACCAGCA-3Ј; p51A4F 5Ј-GATCCCAT CACAGGAAGAC-3Ј and p51A4R 5Ј-TCTGATGCTATCTT CATCCG-3Ј; p51A5F 5Ј-ATGAACCGCCGTCCAATT-3Ј and p51A5R 5Ј-GTGCTGAGGAAGGTACTG-3Ј; p51A6F 5Ј-GGC CGTGAGACTTATGAAAT-3Ј and p51A6R 5Ј-CACTTAAAAT-ATAGAGATAGGGC-3Ј; p51B7F 5Ј-ACCAGCACTTACTTCA-GAAA-3Ј and p51B7R 5Ј-CATGGAGTAATGCTCAATCT-3Ј; and p51B8F 5Ј-ATCATGTCTGGACTATTTCA-3Ј and p51B8R 5Ј-AGGAAGAGCTCACATGGTGA-3Ј. PCR for six sets of p51A was performed as follows: preheating at 96°C for 3 min, followed by 35 cycles of 96°C for 30 s, 53°C for 30 s, and 72°C for 1 min, with a final extension at 72°C for 5 min. The PCR products were denatured at 98°C for 5 min. PCR for two sets of p51B was performed as follows: preheating at 94°C for 2 min, followed by 35 cycles of 94°C for 1 min, 56°C for 1 min, and 72°C for 1 min, with a final extension at 72°C for 5 min. The PCR products were denatured at 94°C for 5 min.
PCR for mutation analysis of the p53 gene
DNA of CML patients was subjected to PCR-SSCP analysis to search for mutations in exons 5-8 of the p53 gene. Primer sets for amplification of four exons of the p53 gene were designed: exon 5 5F 5Ј-TTCCTCTTCCTACAGTACTCC-3Ј and 5R 5Ј-GCCCCAGCTGCTCACCATCGC-3Ј; exon 6 6F 5Ј-CACTGATT GCTCTTAGGTCTG-3Ј and 6R 5Ј-AGTTGCAAACCAGACC TCAGG-3Ј; exon 7 7F 5Ј-CCAAGGCGCACTGGCCTCATC-3Ј and 7R 5Ј-TCAGCGGCAAGCAGAGGCTGG-3Ј; and exon 8 8F 5Ј-CCTATCCTGAGTAGTGGTAAT-3Ј and 8R 5Ј-GTCCTGCTTGCTTACCTCGCT-3Ј. PCR was performed as follows: exons 5, 6 and 8 for 35 cycles at 94°C for 30 s, 60°C for 1 min, and 72°C for 1 min; and exon 7 for 35 cycles at 94°C for 30 s, 70°C for 1 min, and 72°C for 1 min. The PCR products were denatured at 80°C for 5 min.
SSCP gel analysis
SSCP analysis was a modification of the method of Orita et al. 18 The 5Ј-ends of primers (100 pmol) were labeled with ␥-32 P (3000 Ci/mmol, NEN) and polynucleotide kinase (5 U, Boehringer-Mannheim) in 10 l of 50 mm Tris-HCl, pH 8.3, 10 mm MgCl 2 , and 5 mm DTT at 37°C for 30 min. The PCR mixture contained 10 pmol of each of the labeled primers, 2 nmol each of four deoxynucleotides, 0.1 g of sample cDNA or DNA, and 0.25 U of Taq polymerase in 10 l of the buffer specified in the GeneAmp kit. The PCR products were mixed with 10 volumes of a loading buffer containing 95% formamide, 20 mm EDTA, 0.05% bromphenol blue, and 0.05% xylene cyanol, denatured at 94°C or 96°C for 5 min, quenched on ice, and applied (1 l/lane) to a 10% polyacrylamide gel containing 90 mm Tris-borate, pH 8.3, 4 mm EDTA, and 10% glycerol. Electrophoresis was performed at 40 W for 3 h at 18°C with cooling using a water jacket. The gel was dried on filter paper and exposed to X-ray film at −80°C for 1-24 h with an intensifying screen.
Sequence analysis of p53 and p51/p63 genes
After the RT-PCR products were separated on 2% agarose gels and stained with ethidium bromide, the amplified fragment was excised from the gel, electroeluted, purified with phenol, and precipitated with ethanol. 14 The fragments were subcloned into the EcoRV site of the pGEM-5Zf (+/−) cloning vector. The transfected cells were plated on to Luria-Beriani (LB)-ampicillin agar plates containing 5-bromo-4-chloro-3-indolyl-␤-d-galactoside (X-gal), isotransferred to fresh LBampicillin agar plates containing X-gal and isopropylthio-␤-dgalactoside, and cultured overnight for secondary selection. White colonies were transferred into 150 ml of LB medium containing 50 mg/ml ampicillin and cultured at 37°C for 4 h. The cultures were sedimented by centrifugation, resuspended in 20 ml of water, and heated at 98°C for 10 min. After centrifugation, the supernatants were amplified by PCR using T7 or SP6 primers. The three to five independent PCR clones were sequenced using a Model 377 ABI sequencer with dye terminators (Perkin Elmer, Warrington, UK). All sequences were confirmed in both orientations. p51/p63 and p53 genes were defined as mutations when two or more clones from the independent PCR products showed the same abnormality of the base sequence.
Statistical analysis
Statistical analysis was performed using the Statview (Brain Power, Calabashes, CA, USA) software package. Comparisons of groups were analyzed using Fisher's exact test for 2 × 2 tables. Values of P Ͻ 0.05 were considered significant.
Results
Expression analysis of the p51/p63 gene
p51/p63 transcripts were detected in 74 of the 80 cases. To distinguish isotypes, detailed information on the isotypes of p51/p63 transcripts, four sets of primers that specifically amplified the TA, ⌬N, ␣, ␤ and ␥ isotypes were used for the RT-PCR analysis (Figure 2) . The results of the analysis are summarized in Table 1 . The ␣ isotype of p51/p63 transcripts was dominantly expressed in 72 of 74 cases, and the ␤ isotype was expressed in 40 of 74 cases, while the ␥ isotype was expressed in only six cases. The analysis of the acidic N-terminus isotype revealed that the TA isotype was expressed in 73 cases, while the ⌬N isotype was expressed in only three cases (data not shown). Both TA and ⌬N isotypes were detected in two cases. In six cases where the p51/p63 transcript was lost, there were no characteristic features of clinical laboratory data, additional chromosomal abnormality or clinical course. No correlation was observed between the isotypes and the clinical phase of CML.
In normal individuals, the ␣ and TA isotypes of p51/p63 were expressed in all the samples, the ␤ isotype was expressed in 10 of the 50 normal cases and the ␥ and ⌬N isotypes were 
Sequence analysis of the p51/p63 gene
Because p51/p63 transcripts were detected in 74 of 80 cases, mutations in the coding region of the p51A/TAp63 ␥ and p51B/TAp63 ␣ transcripts of these 74 cases were screened by RT-PCR-SSCP. Eight cases (C3, C8, C21, C28, C40, C47, C55 and C60) showed aberrant bands on SSCP gels. In four cases (C8, C21, C28 and C47), these p51/p63 gene mutations could be analyzed from the samples of both CP and BC. Aberrant bands were detected at both phases of C8. As shown in Figure  3 , aberrant bands were detected at only BC phase of C21, C28 and C47. C21 showed only aberrant bands on SSCP gel, indicating one allele deletion of the p51/p63 gene or the same homozygous point mutation. C28 and C47 showed an aberrant band in addition to the normal band, indicating heterozygosity. Sequencing of the DNA fragments that showed aberrant bands on the PCR-SSCP gels revealed five missense mutations (C8, C21, C28, C55 and C60), one base deletion (C47) and three base insertions (C55), as summarized in Table 2 . A silent mutation at codon 248 was detected in two cases (C3 and C40). Only the p51B/TAp63 ␣ isotype of the six p51/p63 transcripts was expressed in all cases with mutations. The mutation was found in both the CP and BC phases of C8 at codon 160, with substitution of AAG to AGG (Lys→Arg) (Figure 4) . In five others cases, a G-base deletion at codon 76 and mutations at codon 105 (ACG→GCG, Thr→Ala), codon 151 (GCC→GTC, Ala→Val), codon 154 (ACG→CAG, Thr→Gln), and codon 170 (ATG→ACG, Met→Arg) were found only in BC ( Figure 4 and Table 2 ). In C47, one G-base deletion at codon 76 led to a frame-shift and a premature stop at codon 78. This mutation results in a truncated p51B/TAp63 ␣ protein lacking the DNA-binding domain to the C-terminal. In C55, insertion of ACG (Thr) between codons 153 and 154 was found ( Figure 4 and Table 2 ). Five of seven missense 
Figure 3
Representative results of RT-PCR-SSCP analysis for mutations of the p51/p63 gene in CML. The primer pair used, p51A2F and p51A2R, amplified a part of the DNA-binding domain of the p51/p63 gene. DNA from patient numbers C21, C28 and C47 exhibit both aberrant and normal bands. These patients were analyzed throughout CP and BC. The arrows indicate aberrant bands having a mutated sequence. C, chronic phase; B, blastic crisis. mutations were within a limited region (codon 151-170) that corresponded to the DNA-binding domain (Figure 1 ).
An examination of mutation and/or polymorphism of the entire coding region of the p51/p63 gene in 50 normal BM or PB samples by the RT-PCR-SSCP method could not detect bandshifts (data not shown). 
Correlation between mutations of the p51/p63 and p53 genes and the clinical phase
The sequences of p53 gene exons 5 to 8 were analyzed in the genomic DNA of 80 CML patients. A two-step strategy based on PCR-SSCP and sequencing followed by PCR-subcloning was employed. Mutations of the p53 gene were found in four cases (C11, C41, C48 and C77) of CML in BC, while no mutations were detected in cases in CP (Table 2 ). In two of these four cases, C11 and C41, mutations of the p53 gene from both CP and BC samples were analyzed. A summary of the mutations of the p53 gene is shown in Table 2 . There were no concurrent mutations of the p51/p63 and p53 genes in any of the CML cases. Frequencies of the p51/p63 and p53 gene mutations were higher in BC (p51/p63 gene, 11.8% (6/51), P Ͻ 0.03; p53 gene, 7.8% (4/51), P Ͻ 0.02) than in CP (p51/p63 gene, 1.5% (1/65); p53 gene, 0% (0/65)) ( Table 3 ). In total, mutations of the p51/p63 and p53 genes were detected in 19.6% (10/51) of samples in BC in contrast to only 1.5% (1/65) in CP. The difference was of very high statistical significance (P Ͻ 0.001).
Discussion
Several studies have investigated the expression of p51/p63 isotypes. 9, 10, 19, 20 The p51/p63 isotypes are expressed in both normal and neoplastic tissues. Bladder, skin, stomach, thymus, and uterus showed expression of all p51/p63 isotypes. Brain, kidney, cervix and lung showed expression of the ⌬N and TAp63 ␥ isotypes, and skeletal muscle showed expression of TAp63 ␣ and TAp63 ␥. 19, 20 However, the expression patterns of p51/p63 isotypes remain unclear in PB, BM, lymph node, and hematological malignancies. The present study revealed that the ␣ isotype of p51/p63 transcripts was dominantly expressed in normal BM, PB, and CML samples, and there was a significant difference in the ␤ isotype expression between the normal control and the CML sample (P Ͻ 0.001; Table 1 ). p51A/TAp63 ␥ functionally transactivated several established p53 reporter genes at approximately 80% of the level of wild-type p53, while p51B/TAp63 ␣ and the ␤ isotype showed no activity related to these p53 reporter genes or to the induction of cell death. 9, 10 These variants act in a dominant-negative manner toward p53 and p51A/TAp63 ␥ transcripts. 9, 10 The present data suggest that there may be an association between predominance of the ␤ isotype expression and leukemogenesis of CML.
The p51B/TAp63 ␣ transcript may contribute to some function other than the function linked to the p51A/TAp63 ␥ and p53 gene. Recently, p51B/TAp63 ␣ and p73 ␣ C-terminal domains were found to be a unique subclass of human sterile alpha motif (SAM)-like domains (Figure 1) . [21] [22] [23] [24] SAM domains are protein-protein interaction modules found in a variety of cytoplasmic signaling proteins and several transcriptional regulatory proteins. 21, 22, 24 In hematological malignancies, aberrant SAM-mediated oligomerization of the TEL, ETS family causes some leukemias in human. 25 Hagiwara et al's 26 mutation was detected in the SAM domain of an ovarian cancer cell line (codon 560, Ser→Ala). The identification of SAM domains at the C-terminal of p51B/TAp63 ␣ enables the design of a new experiment to elucidate the function of these important families having SAM domains in a structural and functional context. Mutation screenings of the p51/p63 gene have been reported in a variety of human malignancies such as non- Table 3 Frequencies of p51/p63 and p53 mutations in CML Waf1/Cip1 and the BAX promoter, but a missense mutation of codon 31 (Gln→His) located outside of the DNA-binding domain was functionally silent. 17, 27 The missense mutations in the DNA-binding domain inactivate downstream transcriptional activity. 27 Our study revealed that all cases with mutations expressed only the p51B/TAp63 ␣ isotype having the SAM domain. This suggests that p51B/TAp63 ␣ may have a biological function in the regulation of hematopoiesis, and further, that the aberrant p51B/TAp63 ␣ may function as an oncogene. More studies will be necessary to clarify the full biological activity of p51B/TAp63 ␣.
Our study showed that five mutations were detected in a limited region of the DNA-binding domain, and that one-base deletion in codon 76 led to a frame-shift which resulted in a truncated p51/p63 protein lacking the DNA-binding domain. Moreover, three reported mutations were also detected near the above-mentioned limited region (Figure 1 ). The DNAbinding domain of the p51/p63 gene is a highly conserved region in the p53 family, 9, 10 and point mutations of the human p53 gene were reported to cluster in four hot spots (affecting residues 175, 245, 248 and 273) within the DNA-binding domain. 28, 29 Considering the sequence homology of the p51/p63 and p53 genes, we hypothesized that this limited region is a hot spot of mutations in the p51/p63 gene ( Figure 1 ).
In the context of the evolution to acute transformation of CML, many oncogenes and tumor suppressor genes have been investigated. The abnormalities so far reported include the p53 gene, 5 36 and the AML1/Evi1 fusion gene. 37 Such a multiplicity of aberrant genes and mechanisms of deregulation suggests that the more advanced clonal evolution characteristic to the blastic transformation of CML can be induced by disruption of diverse cellular signal pathways. It is likely, therefore, that multiple and alternative molecular defects underlie the acute transformation of CML rather than the single universal mechanism, Philadelphia abnormality, at initiation of the disease. Our present study indicates a significant role of p51B/TAp63 ␣ gene mutation in CML patients coincident with the evolution to BC (Figure 3 and Table 3 ). Our study also suggests the possibility that the p51B/TAp63 ␣ gene has some function in leukocyte maturation. The p51/p63 gene mutation may act similarly to the p53 gene mutation as a genetic alteration potentially responsible for the progression of CML.
